Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Clinical trial NCT02612454 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02612454
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-15
- Primary completion
- 2026-10-07
- Enrollment
- 880
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.